A Phase I Trial of a Single ProHema CB Product (Ex Vivo Modulated Human Cord Blood Cells) as Part of Single Cord Blood Unit Transplant after Busulfan/Cyclophosphamide/ATG Conditioning for Pediatric Patients with Inherited Metabolic Disorders
Clinical Trial Grant
Administered By
Institutes and Centers
Awarded By
Fate Therapeutics
Start Date
May 1, 2015
End Date
April 4, 2019
Administered By
Institutes and Centers
Awarded By
Fate Therapeutics
Start Date
May 1, 2015
End Date
April 4, 2019